- Home
- A-Z Publications
- Current Pharmaceutical Biotechnology
- Previous Issues
- Volume 8, Issue 6, 2007
Current Pharmaceutical Biotechnology - Volume 8, Issue 6, 2007
Volume 8, Issue 6, 2007
-
-
Introduction: RNA and The Treatment of Human Cancer
More LessEpigenetic events are important in carcinogenesis and for the susceptibility of malignant cells to chemotherapy, and this knowledge has identified a new generation of oncogenes and thereby also a new class of possible therapeutic targets for anticancer treatment. RNA reflects gene expression and can thereby be used for identification of therapeutic targets through global gene expression analysis or siRNA screening. However, Read More
-
-
-
MicroRNAs in Tumorigenesis
Authors: Kai O. Skaftnesmo, Lars Prestegarden, David R. Micklem and James B. LorensEmerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with sev Read More
-
-
-
RNA Base Damage and Repair
Elaborate repair pathways counteract the deleterious effects of DNA damage by mechanisms that are understood in reasonable detail. In contrast, repair of damaged RNA has not been widely explored. This may be because aberrant RNAs are generally assumed to be degraded rather than repaired. The reason for this view is well founded, since conserved surveillance mechanisms that degrade abnormal RNAs are thoroughl Read More
-
-
-
p53 Family Isoforms
More Lessp63, p73 and p53 are transcription factors members of the p53 gene family involved in development, differentiation and cell response to stress. p53 gene is mutated in 50% of human cancer. Moreover, when p53 gene is not mutated then its tumour suppressor pathway is lost through interaction with abnormally expressed cellular protein or viral protein. Therefore p53 pathway inactivation is a common denominator to Read More
-
-
-
RNAi Screening for Therapeutic Targets in Human Malignancies
Authors: David R. Micklem and James B. LorensThe advent of RNA interference (RNAi) based library screening approaches has sparked a surge in loss-of-function genetic screens. Several recent screens have aimed to identify novel regulators of cancer-related phenotypes. These employ various tumor cell types to model malignant cell functions and use different RNAi effector library approaches to reveal a cache of novel tumor regulators. This review surveys recent RN Read More
-
-
-
Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Global gene expression analysis by way of DNA microarrays and real time quantitative PCR provides an important supplement to established diagnosis and classification of malignant disease. A comprehensive molecular understanding of the regulatory modules involved in carcinogenesis should also be important for improved identification of therapeutic targets and thus for future individualized therapy, e.g., by allowing th Read More
-
-
-
Ultrasound-Directed Drug Delivery
Authors: Michiel Postema and Odd H. GiljaIt has been proven, that the cellular uptake of drugs and genes is increased, when the region of interest is under ultrasound insonification, and even more when a contrast agent is present. This increased uptake has been attributed to the formation of transient porosities in the cell membrane, which are big enough for the transport of drugs into the cell (sonoporation). Owing to this technique, new ultrasound contrast agents tha Read More
-
-
-
Photochemical Internalization: A New Tool for Drug Delivery
The utilisation of macromolecules in the therapy of cancer and other diseases is becoming increasingly important. Recent advances in molecular biology and biotechnology have made it possible to improve targeting and design of cytotoxic agents, DNA complexes and other macromolecules for clinical applications. In many cases the targets of macromolecular therapeutics are intracellular. However, degradation of macromol Read More
-
-
-
Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy
Authors: Bjorn T. Gjertsen, Therese Bredholt, Nina Anensen and Olav Karsten VintermyrRegulation of cell death (apoptosis) is frequently affected in the development of malignant diseases, and all molecular steps from extracellular signalling receptors through intracellular pathways, cell death rheostats and cell death executioners may be involved. Bcl-2 is an anti-apoptotic member of a family of anti- and pro-apoptotic proteins that is upregulated in a variety of cancers and specifically overexpressed throug Read More
-
-
-
Epigenetic Lesions in Malignant Melanoma
Authors: M. Schwabe and M. LubbertMalignant melanoma arises through a series of genetic and epigenetic events. A more profound understanding of the biology of metastatic melanoma should greatly aid in the development of new and effective treatments. Currently, avenues being pursued to improve treatment of metastatic melanoma include dendritic cell vaccines and other vaccination strategies, tyrosine kinase inhibitors, adoptive transfer of ex Read More
-
-
-
Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Authors: O. Bruserud, C. Stapnes, E. Ersvær, B. T. Gjertsen and A. RyningenCharacterization of epigenetic events in carcinogenesis has led to the discovery of a new class of oncogenes and thereby a new class of therapeutic targets. Among the new therapeutic approaches are modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). HDACs deacetylate histones as well as transcription factors and can modulate gene expression through both these mechanism Read More
-
-
-
Epigenetic Targeting in Acute Myeloid Leukemia: Use of Flow Cytometry in Monitoring Therapeutic Effects
Authors: Anita Ryningen and Oystein BruserudFlow cytometric techniques have emerged as a powerful tool in hematology allowing fast, sensitive and reproducible multiparametric analyses at the single cell level of heterogeneous samples. Small subsets of cells can be studied with high degree of accuracy, and a broad and constantly increasing specter of antibodies is available. Flow cytometry has therefore become the method of choice for evaluation of therapeutic e Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cpb
Journal
10
5
false
en
